News search
|
Research 2 Jul 2025 CNIC researchers have uncovered the evolutionary logic of the OxPhos system—the cell’s “engine”—and developed a tool to detect mutations that cause mitochondrial disease |
|
About the CNIC 17 Jun 2025 The projects—led by Drs Almudena Ramiro, José Antonio Enríquez, and Silvia Priori—will receive a total of €5.25 million for CNIC research over the next 5 years |
|
Research 5 Jun 2025 This new tool will advance the development of treatments for congenital muscle diseases and cardiomyopathies. |
|
Research 29 May 2025 CNIC researchers have discovered that the heart is formed from two independent cell types that act in synchrony from the onset of gastrulation. This finding could help to better understand the origin of certain congenital heart defects and open up new opportunities in regenerative medicine and tissue bioengineering. |
|
Research 14 Apr 2025 A study led by the Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), in collaboration with the Instituto de Investigación Biomédica de Barcelona (IRB Barcelona), has identified the most effective subtype of dendritic cell for generating immune memory in response to cancer |
|
Research 9 Apr 2025 A CNIC team has developed an innovative gene therapy strategy for arrhythmogenic right ventricular cardiomyopathy type 5 (ARVC5), a rare and deadly inherited condition that particularly affects young men |
|
Research 2 Apr 2025 Scientists at the CNIC and the University of Bern have found that heart surgery in male mice early in life creates a "memory" passed down to the next generation. Published in Circulation, the study suggests that a parental history of heart surgery should be considered when evaluating cardiovascular health in descendants. |
|
About the CNIC 18 Mar 2025 The CNIC has been allocated €405,625 for its involvement in GRACE, a project focused on developing innovative strategies to improve the detection and management of cardiovascular diseases. |
|
About the CNIC 11 Mar 2025 |
|
Research 4 Feb 2025 The study, published in JACC: CardioOncology, shows that administration of the SGLT2 inhibitor empagliflozin to pigs receiving anthracyclines preserves mitochondrial function, improves myocardial energetics, and prevents degenerative changes in heart structure |
- ‹ previous
- 2 of 15
- next ›
















